RESEARCH TRIANGLE PARK –  Alzheimer’s Disease and dementia have long been feared by many, especially those with first-hand experience. Vik Chandra, CEO and co-founder of uMETHOD is familiar with this disease having seen it in both his grandmother and mother-in-law. According to Chandra, there are 17 and a half million Medicare-aged patients somewhere on a spectrum of cognitive decline, and about 150,000 doctors across the country caring for these patients. He is passionate…READ MORE

Quest Diagnostics unveiled a new artificial intelligence-based test service in the U.S. that aims to help physicians improve the detection of dementia and create better outcomes for patients. Through a partnership with Raleigh, N.C.-based health technology company uMETHOD Health, the Secaucus-headquartered testing provider added the RestoreU Dementia Panel to its testing portfolio, according to a May 4 announcement. Dr. Michael Racke, Quest’s neurology medical director, said, “With so much attention on emerging therapies for…READ MORE

Secaucus, NJ and Raleigh, NC – May 4, 2023 – Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced nationwide availability of the RestoreU™ Dementia Panel, a risk assessment and care plan service created by uMETHOD Health, a health technology company specializing in precision medicine for chronic diseases, to help physicians close care gaps for patients with cognitive decline. The RestoreU service employs artificial intelligence…READ MORE

uMETHOD Health, a precision-medicine software company based in the Research Triangle of North Carolina, is pleased to announce enhancements to their customized care plans that streamline the process for administering cognitive care. The new features consist of eight checklist-style “compliance elements.”  These components assist physicians in completing the required service elements for the Cognitive Assessment and Care Plan (CACP) developed by the U.S. Centers for Medicare and Medicaid Services (CMS).…READ MORE

Frontotemporal Dementia (FTD) is a neurodegenerative disease that affects two brain structures:  the frontal lobes and the temporal lobes. The location of damage is distinct from that of Alzheimer’s Disease (AD), which is characterized by the degeneration of the brain structure known as the hippocampus. For each of these conditions, neurodegeneration can be readily quantified by the amount of shrinkage (loss of tissue) in these structures, which can be observed…READ MORE

In February 2022, Dr. Federico Canavosio of Integrative Medical Care (IMC) in Vero Beach, FL started applying a new approach to memory care for patients aged 60 and older. IMC began working with medical AI company uMETHOD Health to deploy RestoreU, an evidence-based care program for patients at risk of developing Alzheimer’s Disease (AD), dementia, or other cognitive issues. “Cognitive impairment and related dementias are difficult to treat because they…READ MORE

uMETHOD is excited to announce the release of its breakthrough methodology -- called ExtND METHOD -- designed to finally provide a prevention solution to the over 70 million women and men in the USA at risk of Alzheimer’s disease and cognitive decline. The complexity of treating and preventing cognitive decline due to dozens of biological mechanisms and hundreds of interventions is now made straightforward through the application of uMETHOD’s proprietary…READ MORE

Most physicians can assess whether a patient is developing Alzheimer’s disease in five minutes, according to the Alzheimer’s Association. But few general practitioners include the screening in checkups, even though it’s covered as a yearly Medicare benefit. “Honestly, most doctors don’t want to find it,” says Tom Leggett, director of business development for Sonora Quest Laboratories in Tempe. “The uncomfortable truth is when you’re a physician and you find moderate…READ MORE

JANUARY 6, 2020 (KTAR News Photo/Griselda Zetino) PHOENIX — Arizona is projected to have one of the fastest growing rates of Alzheimer’s disease in the country over the next few years, and a clinical lab testing company in the Valley is trying to reverse that. Phoenix-based Sonora Quest Laboratories is working with a tech company called uMETHOD Health to collect patient data through a platform called RestoreU METHOD. The data…READ MORE

At the 2019 Alzheimer’s Association International Conference, July 14-18, in Los Angeles, California, uMETHOD Health shared results from an analysis that evaluated the implementation of a precision-medicine platform to create personalized, multidomain care plans for the treatment of dementia and mild Alzheimer disease. The algorithms analyze medication interactions and adverse drug reactions, such as drug-drug interactions, opioid usage, anticholinergic cognitive burden, and depression-inducing drugs, rate them using input from an open-source…READ MORE